Sort   by:  
 Page size 
UnknownSequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
Not available
S-EPMC3236650 | biostudies-literature
UnknownSurgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
Not available
S-EPMC4652014 | biostudies-literature
UnknownFirst-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Not available
S-EPMC5648176 | biostudies-literature
UnknownTreatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Not available
S-EPMC4289722 | biostudies-literature
UnknownQuality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Not available
S-EPMC5815404 | biostudies-literature
TranscriptomicsReal-time quantitative PCR analysis of hormone-receptor-negative primary breast tumors
Total RNA was extracted from FFPE samples of 139 chemotherapy-naïve hormone-receptor-negative breast cancers pooled from three sample sources and assayed for the expression of 21 genes within two previously reported microarray-derived prognostic signatures in 6 RT-PCR multiplexes. RT-PCR gene expre...
ORGANISM(S): Homo sapiens 
2013-10-25 | E-GEOD-51630 | biostudies-arrayexpress
UnknownBRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
Not available
S-EPMC6067803 | biostudies-literature
UnknownExemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Not available
S-EPMC3612593 | biostudies-literature
UnknownQuality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.
Not available
S-EPMC4879707 | biostudies-literature
GenomicsA Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.

Source of Patients
The source of the patients for this genome-wide case control study was MA.27, which was conducted as a multi-cooperative group effort under the auspices of the NCI Breast Cancer Intergroup of North America. The NCIC Clinical Trials Group (CTG) serves as the co...

phs000210.v1.p1 | EGA
Sort   by:  
 Page size